

RECEIVED
CENTRAL FAX CENTER

NOV 13 2006

PATENT

Appl. No. 10/815,425
Amdt. dated November 13, 2006
Reply to Office Action of May 18, 2006

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-8. Canceled.

9. (Previously presented) A method of inhibiting progression in a patient of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of an inhibitor of soluble epoxide hydrolase ("sEH").

10. (Previously presented) A method of claim 9, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

11. (Previously presented) A method of claim 9, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

12. (Previously presented) A method of claim 9, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

13. (Previously presented) A method of claim 9, wherein the condition is asthma.

14. (Previously presented) A method of claim 9, wherein said inhibitor of sEH is selected from the group consisting of an adamantyl dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).

15. (Previously presented) A method of claim 9, wherein the inhibitor is in a slow release formulation.

Appl. No. 10/815,425
Amdt. dated November 13, 2006
Reply to Office Action of May 18, 2006

PATENT

16. (Previously presented) A method of claim 9, further comprising administering a *cis*-epoxyeicosatrienoic acid ("EET").
17. (Previously presented) A method of claim 9, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.
18. (Previously presented) A method of claim 9, wherein said EET is 14R,15S-EET.
19. (Withdrawn) A method of inhibiting progression in a patient of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of a nucleic acid that inhibits expression of soluble epoxide hydrolase ("sEH").
20. (Withdrawn) A method of claim 19, wherein the nucleic acid is a small interfering RNA.
21. (Withdrawn) A method of claim 19, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.
22. (Withdrawn) A method of claim 19, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.
23. (Withdrawn) A method of claim 19, wherein the interstitial lung disease is one associated with occupational exposure to a dust.
24. (Withdrawn) A method of claim 19, wherein the condition is asthma.
25. (Original) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, said method comprising administering an inhibitor of soluble epoxide hydrolase ("sEH") and a *cis*-epoxyeicosatrienoic acid ("EET") to a person in need thereof.

Appl. No. 10/815,425
Amdt. dated November 13, 2006
Reply to Office Action of May 18, 2006

PATENT

26. (Original) A method of claim 25, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

27. (Original) A method of claim 25, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

28. (Original) A method of claim 25, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

29. (Original) A method of claim 25, wherein the condition is asthma.

30. (Original) A method of claim 25, wherein the inhibitor of sEH or the EET, or both, is in a material which releases the inhibitor over time.

31. (Original) A method of claim 25, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

32. (Original) A method of claim 25, wherein said EET is 14R,15S-EET.

33. (Original) A method of claim 25, wherein the inhibitor is administered orally.

34. (Original) A method of claim 25, wherein the inhibitor is administered in a total daily dose from about 0.001 mg/kg to about 100 mg/kg body weight.

35. (Original) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, said method comprising administering to a person in need thereof a nucleic acid which inhibits expression of a gene encoding soluble epoxide hydrolase ("sEH"), and a cis-epoxyeicosatrienoic acid ("EET").

Appl. No. 10/815,425
Amdt. dated November 13, 2006
Reply to Office Action of May 18, 2006

PATENT

36. (Original) A method of claim 35, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

37. (Original) A method of claim 35, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

38. (Original) A method of claim 35, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

39. (Original) A method of claim 35, wherein the condition is asthma.

40. (Withdrawn) A method of claim 35, wherein the nucleic acid is a small interfering RNA ("siRNA").

41. (New) A method of reducing infiltration of neutrophils into a lung of a patient suffering from a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of an inhibitor of soluble epoxide hydrolase ("sEH").

42. (New) A method of claim 41, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

43. (New) A method of claim 41, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

44. (New) A method of claim 41, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

45. (New) A method of claim 41, wherein the condition is asthma.

Appl. No. 10/815,425
Amdt. dated November 13, 2006
Reply to Office Action of May 18, 2006

PATENT

46. (New) A method of claim 41, wherein said inhibitor of sEH is selected from the group consisting of an adamantyl dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).

47. (New) A method of claim 41, wherein the inhibitor is in a slow release formulation.

48. (New) A method of claim 41, further comprising administering a cis-epoxyeicosatrienoic acid ("EET").

49. (New) A method of claim 41, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

50. (New) A method of claim 41, wherein said EET is 14R,15S-EET.